Reimbursement to Determine Future Course of European Continuous Glucose Monitoring Systems Market

The European market for continuous glucose monitoring systems is in its nascent phase. Despite its promising potential, industry participants remain wary due to concerns over reimbursement and acceptance by conservative clinicians. However, the projected integration of continuous glucose monitoring systems with insulin pumps will support market expansion.

Frost & Sullivan (http://www.patientmonitoring.frost.com) finds that the European Continuous Glucose Monitoring Systems Market earned revenues of $14.0 million in 2006 and is likely to reach $ 30 million in 2009.

"Currently in the innovation stage of the product life cycle, the European continuous glucose monitoring systems market is witnessing considerable activity to quickly and effectively meet unmet demand," says Frost & Sullivan Industry Analyst Aarati Ajay. "Attracted by its considerable potential, the industry encompasses an interesting mix of participants ranging from multi-billion dollar global conglomerates such as Abbott Labs, Medtronic, and Johnson & Johnson, to very small technology innovators such as Cybiocare, Sontra, and SpectRx."

Devising a method that involves minimum or no discomfort to the patient, while monitoring blood glucose levels is the biggest challenge facing market participants today. Already, technology initiatives are underway to develop systems that offer reliable and accurate information on glucose levels while causing minimal or no inconvenience to patients. Another major challenge is the cost attached to the use of such devices.

"Currently, there are only three products available in the market and all of them are based on a model in which the sensors need to be changed every few days," explains Ms. Ajay. "Sensors are expensive and add significantly to the total cost of using the system."

Moreover, the inclusion of such systems under the reimbursable category is widely debated since, at present, these devices are useful only to a very small section of the patient population.

A proactive approach to technology development will ensure success in this largely untapped market. Companies able to introduce affordable and user-friendly devices rapidly will capture the majority of this exciting market.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Continuous Glucose Monitoring Systems Market (M011- 56) then send an e-mail to Radhika Menon Theodore- Corporate Communications at This email address is being protected from spambots. You need JavaScript enabled to view it. with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

European Continuous Glucose Monitoring Systems Market is part of the Patient Monitoring Subscription, which also includes research in the following markets: European Market for Telemedicine, European Market for Wireless Patient Monitoring and, European Neurological Monitors Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

Most Popular Now

AI in Personalized Cancer Medicine: New …

The application of AI in precision oncology has so far been largely confined to the development of new drugs and had only limited impact on the personalisation of therapies. New...

AI can Predict Brain Cancer Patients…

Artificial Intelligence (AI) can predict whether adult patients with brain cancer will survive more than eight months after receiving radiotherapy treatment. The use of the AI to successfully predict patient outcomes...

Max Planck Institute for Informatics and…

The Max Planck Institute for Informatics and Google deepen their strategic research partnership. With additional financial support from the U.S. IT company, the "Saarbr├╝cken Research Center for Visual Computing, Interaction...

JMIR Medical Informatics Invites Submiss…

JMIR Publications has announced a new section titled, "AI Language Models in Health Care" in JMIR Medical Informatics. This leading peer-reviewed journal is indexed in PubMed and has a unique...

Paper Calls for Patient-First Regulation…

Ever wonder if the latest and greatest artificial intelligence (AI) tool you read about in the morning paper is going to save your life? A new study published in JAMA...

Could ChatGPT Help or Hurt Scientific Re…

Since its introduction to the public in November 2022, ChatGPT, an artificial intelligence system, has substantially grown in use, creating written stories, graphics, art and more with just a short...

Evaluating the Performance of AI-Based L…

A new study evaluates an artificial intelligence (AI)-based algorithm for autocontouring prior to radiotherapy in head and neck cancer. Manual contouring to pinpoint the area of treatment requires significant time...

Making AI a Partner in Neuroscientific D…

The past year has seen major advances in Large Language Models (LLMs) such as ChatGPT. The ability of these models to interpret and produce human text sources (and other sequence...

Chapman Scientists Code ChatGPT to Desig…

Generative artificial intelligence platforms, from ChatGPT to Midjourney, grabbed headlines in 2023. But GenAI can do more than create collaged images and help write emails - it can also design...

DMEA nova Award: Wanted - Visionary Solu…

9 - 11 April 2024, Berlin, Germany. The DMEA nova Award is being presented at DMEA 2024 for the first time. The award honours a digital health startup for an outstanding...

New Digital Therapy Reduces Anxiety and …

A therapist-guided digital cognitive behavioural therapy reduced distress in 89 per cent of participants living with long-term physical health conditions, a new King's College London study finds. Researchers at the Institute...

Europe's Digital Health Industry Me…

9 - 11 April 2024, Berlin, Germany. In just over two months, from 9 to 11 April 2024, DMEA, Europe's leading event for digitalisation of healthcare, will gather digital health experts...